O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Kreth, Simone ^a   Thon, Niklas ^a   Eigenbrod, Sabina ^a   Lutz, Juergen ^a   Ledderose, Carola ^b   Egensperger, Rupert ^a   Tonn, Joerg C ^a   Kretzschmar, Hans A ^a   Hinske, Ludwig C ^a   Kreth, Friedrich W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPREGULATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BRAIN TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENETICS; GLIOMA; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VALIDATION STUDY;

EUKARYOTA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RADIOTHERAPY, ADJUVANT; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 79951993228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017156     Document Type: Article

References (33)

1. Ohgaki H, Kleihues P, (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996 352/10/987 [pii]; 10.1056/NEJMoa043330 [doi].
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466 S1470-2045(09)70025-7 [pii]; 10.1016/S1470-2045(09)70025-7 [doi].
4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de TN, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003 352/10/997 [pii]; 10.1056/NEJMoa043331[doi].
5. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, et al. (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880 JCO.2009.23.6497 [pii]; 10.1200/JCO.2009.23.6497[doi].
6. Kaina B, Christmann M, Naumann S, Roos WP, (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6: 1079-1099 S1568-7864(07)00124-3 [pii]; 10.1016/j.dnarep.2007.03.008 [doi].
7. Spiegl-Kreinecker S, Pirker C, Filipits M, Lotsch D, Buchroithner J, et al. (2010) O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 12: 28-36 nop003 [pii]; 10.1093/neuonc/nop003 [doi].
8. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, et al. (2010) MGMT activity, promoter methylation and immunohistochemistry of pre-treatment and recurrent malignant gliomas: A comparative study on astrocytoma and glioblastoma. Int J Cancer 10.1002/ijc.25229 [doi].
9. Preusser M, Charles JR, Felsberg J, Reifenberger G, Hamou MF, et al. (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18: 520-532 BPA153 [pii]; 10.1111/j.1750-3639.2008.00153.x [doi].
10. Everhard S, Tost J, El AH, Criniere E, Busato F, et al. (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11: 348-356 15228517-2009-001 [pii]; 10.1215/15228517-2009-001[doi].
11. Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, et al. (2002) The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene 21: 4822-4829 10.1038/sj.onc.1205581 [doi].
12. Girault I, Tozlu S, Lidereau R, Bieche I, (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9: 4415-4422.
13. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, et al. (2006) Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 119: 288-296 10.1002/ijc.21807 [doi].
14. Karnofsky DA, Burchenal JH, (1949) The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM, editors. Evaluation of Chemotherapeutic Agents Columbia Univ Press.
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG, (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
16. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, et al. (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197 26/13/2192 [pii]; 10.1200/JCO.2007.14.8163 [doi].
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109 10.1007/s00401-007-0243-4 [doi].
18. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, et al. (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392-401 S1470-2045(06)70665-9 [pii]; 10.1016/S1470-2045(06)70665-9 [doi].
19. Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, et al. (2009) Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol 68: 1219-1228 10.1097/NEN.0b013e3181bee1f1 [doi].
20. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, et al. (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121: 2458-2464 10.1002/ijc.23020 [doi].
21. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G, (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: 379-385 10.1002/ijc.20575 [doi].
22. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
23. Kreth S, Heyn J, Grau S, Kretzschmar HA, Egensperger R, et al. (2010) Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro Oncol 12: 570-579 nop072 [pii]; 10.1093/neuonc/nop072 [doi].
24. Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, et al. (2010) Predominant influence of MGMT methylation in non-resectable GBM after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry in press.
25. Kaplan E, Meier P, (1958) Non parametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481.
26. Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, et al. (2007) Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 67: 8952-8959 67/18/8952 [pii]; 10.1158/0008-5472.CAN-06-3820 [doi].
27. Ushijima T, (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231 nrc1571 [pii]; 10.1038/nrc1571 [doi].
28. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, et al. (1999) The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27: 2291-2298 gkc377 [pii].
29. Kim H, Kwon YM, Kim JS, Han J, Shim YM, et al. (2006) Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 107: 1042-1049 10.1002/cncr.22087 [doi].
30. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, et al. (2010) The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 120: 521-532 40706 [pii]; 10.1172/JCI40706 [doi].
31. Lorente A, Mueller W, Urdangarin E, Lazcoz P, Lass U, et al. (2009) RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 19: 279-292 BPA185 [pii]; 10.1111/j.1750-3639.2008.00185.x [doi].
32. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622 clinchem.2008.112797 [pii]; 10.1373/clinchem.2008.112797 [doi].
33. Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, et al. (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32: 1220-1227 10.1097/PAS.0b013e318164c3f0 [doi].